Evidence map›Paper›PMID 28185131›Full record

ArticleInternal and emergency medicine2017

External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans.

Christine G Kohn, Erin R Weeda, Neela Kumar, Philip S Wells, W Frank Peacock, Gregory J Fermann, Li Wang, Onur Baser, Jeff R Schein, Concetta Crivera and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Charlson and Elixhauser Comorbidity Indices for Prediction of Mortality and Hospital Readmission in Patients With Acute Pulmonary Embolism.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Christine G KohnSchool of Pharmacy, University of Saint Joseph, Hartford, CT, USA.
Erin R WeedaSchool of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT, 06269, USA.
Neela KumarSchool of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Philip S WellsDepartment of Medicine, University of Ottawa, Ottawa, ON, USA.
W Frank PeacockDepartment of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
Gregory J FermannDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA.
Li WangSTATinMed Research, Plano, TX, USA.
Onur BaserSTATinMed Research, Plano, TX, USA.
Jeff R ScheinHealth Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ, USA.
Concetta CriveraHealth Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ, USA.
Craig I ColemanSchool of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT, 06269, USA. craig.coleman@hhchealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients at low risk of early complications using claims data. We sought to externally validate the IMPACT and simplified Pulmonary Embolism Severity Index (sPESI) tools for predicting all-cause mortality and readmission. We used Veteran Health Administration data (10/1/2010-9/30/2015) to identify adults with ≥1 inpatient diagnosis code for acute PE, ≥12 months continuous medical and pharmacy benefits prior to the index PE, ≥90 days of post-event follow-up (unless death occurred) and ≥1 claim for an anticoagulant during the index PE stay. Prognostic accuracies of IMPACT and sPESI for 30- and 90-day all-cause mortality and 90-day readmission were estimated. Of 6,746 PE patients, 7.5 and 12.6% died at 30 and 90 days. Within 90 days, 20.1% were readmitted for any reason. Hospitalization for recurrent VTE and major bleeding occurred in 5.6 and 1.7% of patients. IMPACT classified 15.2% as low risk, while 28.4% were low risk per sPESI. Both tools displayed sensitivity >90% and negative predictive values (NPVs) >97% for 30-day mortality, but low specificity (range 16.2-30.0) and positive predictive values (PPVs) (range 8.7-9.5); with similar results observed for 90-day mortality. IMPACT's sensitivity for all-cause readmission was numerically higher than sPESI (88.2 vs. 79.0%), but both had comparable NPVs (85.1 vs. 84.2%). Similar trends were observed for VTE or major bleeding readmissions. IMPACT classified patients for post-PE outcomes with similar accuracy as sPESI. IMPACT appears useful for identifying PE patients at low risk for early mortality or readmission in claims-based studies.

Indexed as

Patient Outcome AssessmentAdolescentAdultAgedFemaleHumansInsurance Claim ReviewMaleMiddle AgedPulmonary EmbolismRisk AssessmentSeverity of Illness IndexUnited StatesUnited States Department of Veterans AffairsVeteransAdministrative claimMortalityPrognosisPulmonary embolismRisk assessmentSeverity of illness index

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.